[ Nemesis Bioscience raises $908.1K ]

Nemesis Bioscience has raised $908.1K in Seed funding.

Founded in 2014, Nemesis Bioscience  develops and commercializes therapeutic agents for clinical, veterinary and industrial sectors. Nemesis Bioscience is advancing Bacterial Cybergenetics technologies in vivo, including: Nemesis Symbiotics for applications including the reversal of antibiotic resistance and Transmids for their clinical, veterinary and industrial delivery.

The company intends to use the funds to validate its suite of technologies.

Funding  Seed
Founded  2014
Country  UK
City  Cambridge
Founder / CEO  Frank Massam
Deal Size  $908.1K
Investors  Rainbow Seed Fund
 Finance Wales
Previous Investors  /